---
schema_version: "secwatch.filing_event.v1"
accession: "0001741830-24-000036"
form_type: "8-K"
ticker: null
cik: "0001741830"
company_name: "Kronos Bio, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:33:37.671218+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kronos Bio Q1 net loss $30M, cash $152M into H2 2026; restructuring charges $12.8M

## Summary
- Net loss of $30.0M ($0.50/share) includes $7.7M stock-based comp; R&D $14.2M, G&A $7.5M.
- Impairment of long-lived assets $6.6M; restructuring expense $6.2M (includes $4.4M stock-based comp).
- Cash, equivalents and investments $152.0M, sufficient into second half of 2026.
- KB-0742 Phase 1/2 update to be presented at ASCO June 1; expansion cohorts on track Q3 2024.
- KB-9558 IND-enabling studies to complete by end 2024; first-in-human expected H1 2025.

## SEC filing metadata
- accession: 0001741830-24-000036
- form_type: 8-K
- cik: 0001741830
- company_name: Kronos Bio, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1741830/000174183024000036/0001741830-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1741830/000174183024000036/kron-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001741830-24-000036
- JSON: https://secwatch.observer/filing/0001741830-24-000036.json
- Plain text: https://secwatch.observer/filing/0001741830-24-000036.txt

## Key facts
- Earnings Releases
  Kronos Bio, Inc. reported the quarter ended March 31, 2024 results: net income $30.0 million, or $0.50 per share, EPS $0.50 per share.
  - Period: the quarter ended March 31, 2024
  - Net income: $30.0 million, or $0.50 per share
  - EPS: $0.50 per share
  - Result: reported results
  source text: Net loss for the first quarter of 2024 was $30.0 million, or $0.50 per share, including non-cash stock-based compensation expense of $7.7 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000174183024000036/0001741830-24-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.